摘要
目的:比较胰岛素泵输注赖脯胰岛素(优泌乐)与重组人胰岛素(优泌林R)治疗初诊2型糖尿病的疗效及安全性。方法:选择45例本院初诊2型糖尿病患者行胰岛素泵强化治疗,并按随机数字表法分为优泌乐组和优泌林R组,比较两组各点血糖、血糖达标时间、血糖达标时胰岛素用量及低血糖发生率。结果:优泌乐组的血糖达标时间较优泌林R组短,胰岛素用量也较少,餐后血糖值更低,差异均有统计学意义(P<0.05);但两组餐前血糖及睡前血糖比较差异无统计学意义(P>0.05)。结论:用胰岛素泵输注优泌乐和优泌林R均能安全、有效的控制初诊2型糖尿病高血糖状态,但优泌乐组血糖达标时间更短,餐后血糖控制更佳,所需胰岛素量更少。
Objective：To compare the efficacy and safety of insulin Lispro and Humulin R via continuous subcutaneous insulin infusion pump on hyperglycemia in newly-diagnosed 2 diabetes. Method：45 patients accepted a 2-week course of intensive CsII were selected. They were divided into group A（n=25）and group B（n=20）according to random number table method. The group A was treated with insulin Lispro,the group B was treated with Humulin R. The therapeutic effects were measured after therapy. Result：The time for good glycemia control was shorter in the group A than that in the group B（P〈0.05）;the mean of three postprandial blood glucose were significantly lower in the group A than that in the group B,with lower total insulin dosage,the differences were statistically significant（P〈0.05）;but no differences in blood glucose between the two groups were observed in bedtime and before three meals（P＆gt;0.05）. Conclusion：Insulin Lispro via continuous subcutaneous insulin infusion pump is as efficacious and safe as Humulin R in controlling hyperglycemia in newly-diagnosed type 2 diabetes,but insulin Lispro provides a more effective and faster control of postprandial hyperglycemia with less insulin used.
出处
《中国医学创新》
CAS
2014年第7期48-50,共3页
Medical Innovation of China
关键词
糖尿病
2型
胰岛素泵
优泌林R
赖脯胰岛素
Diabetes mellitus
Type 2
Insulin pump
Iinsulin Lispro
Humulin R
